Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization - PubMed (original) (raw)
. 1997 Jul 4;272(27):17118-25.
doi: 10.1074/jbc.272.27.17118.
Affiliations
- PMID: 9202030
- DOI: 10.1074/jbc.272.27.17118
Free article
Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization
P Giannakakou et al. J Biol Chem. 1997.
Free article
Abstract
Acquired resistance to paclitaxel can be mediated by P-glycoprotein or by alterations involving tubulin. We report two paclitaxel-resistant sublines derived from 1A9 human ovarian carcinoma cells. Single-step paclitaxel selection with verapamil yielded two clones that are resistant to paclitaxel and collaterally sensitive to vinblastine. The resistant sublines are not paclitaxel-dependent, and resistance remained stable after 3 years of drug-free culture. All cell lines accumulate [3H]paclitaxel equally, and no MDR-1 mRNA was detected by polymerase chain reaction following reverse transcription. Total tubulin content is similar, but the polymerized fraction increased in parental but not in resistant cells following the paclitaxel addition. Purified tubulin from parental cells demonstrated paclitaxel-driven increased polymerization, in contrast to resistant cell tubulin, which did not polymerize under identical conditions. In contrast, epothilone B, an agent to which the resistant cells retained sensitivity, increased assembly. Comparable expression of beta-tubulin isotypes was found in parental and resistant cells, with predominant expression of the M40 and beta2 isotypes. Sequence analysis demonstrated acquired mutations in the M40 isotype at nucleotide 810 (T --> G; Phe270 --> Val) in 1A9PTX10 cells and nucleotide 1092 (G --> A; Ala364 --> Thr) in 1A9PTX22 cells. These results identify residues beta270 and beta364 as important modulators of paclitaxel's interaction with tubulin.
Similar articles
- A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells.
Giannakakou P, Gussio R, Nogales E, Downing KH, Zaharevitz D, Bollbuck B, Poy G, Sackett D, Nicolaou KC, Fojo T. Giannakakou P, et al. Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2904-9. doi: 10.1073/pnas.040546297. Proc Natl Acad Sci U S A. 2000. PMID: 10688884 Free PMC article. - Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol(R)).
Kowalski RJ, Giannakakou P, Hamel E. Kowalski RJ, et al. J Biol Chem. 1997 Jan 24;272(4):2534-41. doi: 10.1074/jbc.272.4.2534. J Biol Chem. 1997. PMID: 8999970 - Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of beta-tubulin (Asp26Glu) and less stable microtubules.
Hari M, Loganzo F, Annable T, Tan X, Musto S, Morilla DB, Nettles JH, Snyder JP, Greenberger LM. Hari M, et al. Mol Cancer Ther. 2006 Feb;5(2):270-8. doi: 10.1158/1535-7163.MCT-05-0190. Mol Cancer Ther. 2006. PMID: 16505100 - Resistance to microtubule-stabilizing drugs involves two events: beta-tubulin mutation in one allele followed by loss of the second allele.
Wang Y, O'Brate A, Zhou W, Giannakakou P. Wang Y, et al. Cell Cycle. 2005 Dec;4(12):1847-53. doi: 10.4161/cc.4.12.2264. Epub 2005 Dec 18. Cell Cycle. 2005. PMID: 16294009 Free PMC article. - Epothilone B and its analogs - a new family of anticancer agents.
Altmann KH. Altmann KH. Mini Rev Med Chem. 2003 Mar;3(2):149-58. doi: 10.2174/1389557033405269. Mini Rev Med Chem. 2003. PMID: 12570848 Review.
Cited by
- Understanding the basis of drug resistance of the mutants of αβ-tubulin dimer via molecular dynamics simulations.
Natarajan K, Senapati S. Natarajan K, et al. PLoS One. 2012;7(8):e42351. doi: 10.1371/journal.pone.0042351. Epub 2012 Aug 7. PLoS One. 2012. PMID: 22879949 Free PMC article. - Improved biochemical strategies for targeted delivery of taxoids.
Ganesh T. Ganesh T. Bioorg Med Chem. 2007 Jun 1;15(11):3597-623. doi: 10.1016/j.bmc.2007.03.041. Epub 2007 Mar 18. Bioorg Med Chem. 2007. PMID: 17419065 Free PMC article. Review. - Taxotere resistance in SUIT Taxotere resistance in pancreatic carcinoma cell line SUIT 2 and its sublines.
Liu B, Staren E, Iwamura T, Appert H, Howard J. Liu B, et al. World J Gastroenterol. 2001 Dec;7(6):855-9. doi: 10.3748/wjg.v7.i6.855. World J Gastroenterol. 2001. PMID: 11854916 Free PMC article. - Emerging targets in cancer drug resistance.
Kumar S, Kushwaha PP, Gupta S. Kumar S, et al. Cancer Drug Resist. 2019 Jun 19;2(2):161-177. doi: 10.20517/cdr.2018.27. eCollection 2019. Cancer Drug Resist. 2019. PMID: 35582722 Free PMC article. Review. - Paclitaxel: Application in Modern Oncology and Nanomedicine-Based Cancer Therapy.
Sharifi-Rad J, Quispe C, Patra JK, Singh YD, Panda MK, Das G, Adetunji CO, Michael OS, Sytar O, Polito L, Živković J, Cruz-Martins N, Klimek-Szczykutowicz M, Ekiert H, Choudhary MI, Ayatollahi SA, Tynybekov B, Kobarfard F, Muntean AC, Grozea I, Daştan SD, Butnariu M, Szopa A, Calina D. Sharifi-Rad J, et al. Oxid Med Cell Longev. 2021 Oct 18;2021:3687700. doi: 10.1155/2021/3687700. eCollection 2021. Oxid Med Cell Longev. 2021. PMID: 34707776 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials